In an otherwise volatile pharmaceutical world, in the UK, 2009 has seen two notable anniversaries, the implementation of the 10th re-negotiated Pharmaceutical Price Regulation Scheme in January and the 10th birthday of the National Institute for Health and Clinical Excellence (NICE) in April (Marketletters passim). PPRS and NICE, are among abbreviations most widely recognized, but their structures, functions, ways of working and inter-relationship are often less than fully understood.
Like them or hate them, these are original, well-established and influential models that governments and industry bodies elsewhere look to. A great deal has changed, but much has not.
One-stop reference
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze